Ian M. McElree
About
Ian M. McElree is a scholar working on Surgery, Urology and Infectious Diseases.
According to data from OpenAlex, Ian M. McElree has authored 26 papers receiving a total of 223 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Surgery, 7 papers in Urology and 5 papers in Infectious Diseases. Recurrent topics in Ian M. McElree's work include Bladder and Urothelial Cancer Treatments (24 papers), Urinary and Genital Oncology Studies (23 papers) and Urological Disorders and Treatments (7 papers). Ian M. McElree is often cited by papers focused on Bladder and Urothelial Cancer Treatments (24 papers), Urinary and Genital Oncology Studies (23 papers) and Urological Disorders and Treatments (7 papers). Ian M. McElree collaborates with scholars based in United States, Germany and Lebanon. Ian M. McElree's co-authors include Vignesh T. Packiam, Michael A. O’Donnell, Ryan L. Steinberg, Sarah L. Mott, Kenneth G. Nepple, Paul T. Gellhaus, Roger Li, Neema Navai, Facundo Davaro and Ashish M. Kamat and has published in prestigious journals such as The Journal of Urology, Cancers and JAMA Network Open.
In The Last Decade
Ian M. McElree
19 papers receiving 221 citations
Hit Papers
Peers
Ian M. McElree
Rohit Chahal United Kingdom
Roberto Carando Italy
Viveka Ströck Sweden
François Xavier Nouhaud France
Jesús Rodríguez Molina Spain
Stilianos Giannakopoulos Greece
Joanna Chorbińska Poland
Paul KH Tam Hong Kong
Seth P. Lerner United States
Ashmi Doshi United States
Citations per year, relative to Ian M. McElree Ian M. McElree (= 1×)
peers
Rohit Chahal
Countries citing papers authored by Ian M. McElree
Since
Specialization
Citations
This map shows the geographic impact of Ian M. McElree's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian M. McElree with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian M. McElree more than expected).
Fields of papers citing papers by Ian M. McElree
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ian M. McElree. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian M. McElree. The network helps show where Ian M. McElree may publish in the future.
Co-authorship network of co-authors of Ian M. McElree
This figure shows the co-authorship network connecting the top 25 collaborators of Ian M. McElree. A scholar is included among the top collaborators of Ian M. McElree based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian M. McElree. Ian M. McElree is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
McElree, Ian M., Ryan L. Steinberg, Helen Y. Hougen, et al.. (2025). Long‐term outcomes of a cascading salvage strategy for high‐risk non‐muscle‐invasive bladder cancer. British Journal of Urology. 137(2). 339–347.
2.
Packiam, Vignesh T., Ian M. McElree, Saum Ghodoussipour, et al.. (2025). Presence of an Artificial Intelligence–powered Predictive Biomarker Is Associated with a Poor Response to Intravesical Bacillus Calmette-Guerin but Not to Intravesical Sequential Gemcitabine/Docetaxel in Patients with High-grade Non–muscle-invasive Bladder Cancer. European Urology Oncology. 8(6). 1461–1465.
3.
McElree, Ian M., Sarah L. Mott, Helen Y. Hougen, et al.. (2025). Bladder-sparing management for high grade noninvasive urothelial carcinoma of the prostate. Urologic Oncology Seminars and Original Investigations. 43(9). 521.e1–521.e8.
4.
McElree, Ian M., Ryan L. Steinberg, Helen Y. Hougen, et al.. (2025). Extended Outcomes of Intravesical Valrubicin and Docetaxel as a Secondary Salvage Treatment for Recalcitrant High-risk Non–muscle-invasive Bladder Cancer. European Urology Focus. 11(6). 951–958.
5.
McElree, Ian M., Ryan L. Steinberg, Helen Y. Hougen, et al.. (2025). THE EFFICACY OF SALVAGE BCG FOR RECURRENT NON-MUSCLE INVASIVE BLADDER CANCER AFTER FIRST-LINE GEMCITABINE AND DOCETAXEL (GEM/DOCE). Urologic Oncology Seminars and Original Investigations. 43(3). 50–50.
6.
McElree, Ian M., Ryan L. Steinberg, Helen Y. Hougen, et al.. (2025). Assessing the efficacy and safety of sequential intravesical gemcitabine and docetaxel – does time from transurethral resection of bladder tumour to induction matter?. British Journal of Urology. 136(1). 42–44.
7.
McElree, Ian M., Ryan L. Steinberg, Sarah L. Mott, et al.. (2025). The role of blue light cystoscopy and additional operative evaluations during first surveillance after induction therapy for high-risk NMIBC. Bladder Cancer. 11(2). 1802636702–1802636702.
8.
McElree, Ian M., et al.. (2024). Early experience with sequential intravesical gemcitabine and docetaxel for micropapillary variant non-muscle invasive bladder cancer. Urologic Oncology Seminars and Original Investigations. 42(9). 289.e13–289.e21.
9.
McElree, Ian M., et al.. (2024). ONCOLOGIC OUTCOMES OF BLADDER-SPARING MANAGEMENT FOR HIGH-GRADE NON-INVASIVE UROTHELIAL CARCINOMA OF THE PROSTATIC URETHRA. Urologic Oncology Seminars and Original Investigations. 42. S45–S46.
10.
McElree, Ian M., Vignesh T. Packiam, Ryan L. Steinberg, et al.. (2024). Sequential Endoluminal Doxorubicin and Gemcitabine Alternating Weekly with Sequential Mitomycin and Docetaxel for Recurrent Non-Muscle Invasive Urothelial Carcinoma. Cancers. 16(24). 4126–4126.
11.
Packiam, Vignesh T., et al.. (2024). The efficacy of sequential intravesical gemcitabine and docetaxel versus BCG for the treatment of European association of urology very-high risk non-muscle invasive bladder cancer. Urologic Oncology Seminars and Original Investigations. 43(6). 390.e13–390.e22.
12.
McElree, Ian M., et al.. (2024). An update on the use of stem cell therapy for erectile dysfunction. Asian journal of urology. 11(4). 530–544.
13.
McElree, Ian M., Sarah L. Mott, Helen Y. Hougen, et al.. (2024). Sequential endoluminal gemcitabine and docetaxel vs. Bacillus Calmette–Guérin for the treatment of upper tract carcinoma in situ. Urologic Oncology Seminars and Original Investigations. 42(7). 221.e9–221.e16.
14.
McElree, Ian M., et al.. (2023). Multi-institutional feasibility and safety outcomes of retroperitoneal robot-assisted partial nephrectomy in morbidly obese patients. Translational Andrology and Urology. 12(5). 700–707.
15.
McElree, Ian M., et al.. (2023). Sequential endoluminal gemcitabine and docetaxel for the treatment of clinically non-invasive high-grade upper tract urothelial carcinoma. Urologic Oncology Seminars and Original Investigations. 42(1). 20.e9–20.e15.
16.
McElree, Ian M., Ryan L. Steinberg, Sarah L. Mott, Michael A. O’Donnell, & Vignesh T. Packiam. (2023). Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non–Muscle-Invasive Bladder Cancer. JAMA Network Open. 6(2). e230849–e230849.
17.
Tan, Wei Shen, Ian M. McElree, Facundo Davaro, et al.. (2023). Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder Cancer. European Urology Oncology. 6(5). 531–534.
18.
McElree, Ian M., et al.. (2023). Sequential intravesical gemcitabine and docetaxel for treatment-naïve and previously treated intermediate-risk nonmuscle invasive bladder cancer. Urologic Oncology Seminars and Original Investigations. 41(12). 485.e1–485.e7.
19.
McElree, Ian M., et al.. (2022). Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer. Urologic Oncology Seminars and Original Investigations. 41(3). 148.e1–148.e7.
20.
Ueda, Atsushi, et al.. (2018). Two novel forms of ERG oscillation in Drosophila : age and activity dependence. Journal of Neurogenetics. 32(2). 118–126.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Rohit Chahal Breakdown of academic impact, for papers by Roberto Carando Breakdown of academic impact, for papers by Viveka Ströck Breakdown of academic impact, for papers by François Xavier Nouhaud Breakdown of academic impact, for papers by Jesús Rodríguez Molina Breakdown of academic impact, for papers by Stilianos Giannakopoulos Breakdown of academic impact, for papers by Joanna Chorbińska Breakdown of academic impact, for papers by Paul KH Tam Breakdown of academic impact, for papers by Seth P. Lerner Breakdown of academic impact, for papers by Ashmi Doshi